About us
Agastiya Biotech is not just another biotech or pharma company. The goal of Agastiya Biotech is to create toxicity-free drugs with maximum efficacy combined with affordable pricing for the global population. Agastiya seeks to accomplish this goal through its new discovery engine that combines ancient natural sciences with quantum biology.
The upcoming India-based Phase 1 clinical study of our AB001 molecule for multiple metastatic cancer patients is expected to bring breakthrough discovery in non-toxic cancer therapy with maximized efficacy in tumor regression. Dr. Pillai, along with his Chief Scientist, Dr. Dinesh have created dozens small molecules for different indications. Agastiya Biotech’s out-of-the box approach in drug discovery and treatment of diseases is an unmet need of our day. Talking about his innovation Dr. Pillai says that his role in drug discovery is to excavate and resurrect what had been done millenniums ago and redeem the rigidity and linearity paradigms of western biotech.
Founder
Dr.Baskaran Pillai
Chairman, Founder
Agastiya Biotech’s founder and inventor, Baskaran Pillai, PhD, is a visionary who synthesizes natural sciences with modern quantum biology and medicinal chemistry.
Dr. Pillai has discovered a few dozen molecules – all of them carry the lowest toxicity or no observable toxicity. The molecules unlike chemotherapy do not harm healthy cells. Dr. Pillai is currently working on a novel technology withing AI technology. His ‘AI Intuit:Serendipty’ is an attempt to program intuition and serendipity using Indian models of higher intelligence.
As a phenomenologist of religion Dr. Pillai has innovated new methods of mythoanalysis across many religions. He carries a Master’s Degree in English Literature, Master of Letters Degree in Comparative Religion, and a PhD (University of Pittsburgh) in Religious Studies.
Dr. Pillai is a multi-disciplinary innovator who combines the wisdom of the Eastern tradition with the Western science and technology. He is the founder of Phonemic Intelligence (“PI”) which traces intelligence to sound waves and brain anatomy, physiology and neurochemistry. fMRI studies of PI sounds is a breakthrough in educational technology with capability to improve the math and science brain areas.
In the field of drug discovery, he is the pioneer to discover femtomedicine for oncology which introduces quantum biology and quantum pharmacology.
Chief Scientific Officer
MG Dinesh
Heading Agastiya Biotech’s cancer stem cell research, Dr. Dinesh holds a PhD in Stem Cell Biology from Sri Ramachandra University in Chennai. He has over 12 years in dedicated stem cell research and drug discovery with many premier institutions resulting in dozens of international and national publications and several patents. Dr. Dinesh conducted a single-arm, open-labeled clinical study with chronic plaque psoriasis patients, in which he also involved in dose preparation, safety, validation and efficacy studies, resulting in the launch of a chronic plaque psoriasis product sold to Lupin Pharmaceuticals.
Director, Interim CEO
Sonja Benkovich
Ms. Benkovich has 30 years of experience in start-up ventures from Wall Street to international India-US enterprises. She has held roles that include founder, C-suite, mergers and acquisitions, Investment Advisory (Series 65), IP protection, legal and corporate compliance, taxation and audit, and government regulatory adherence. Working with Agastiya founder Dr. Pillai, she was part of the acquisition team of Vopec Pharmaceuticals and East West Integrative Research Institute, where she is an Independent Board member.
Medical Advisory Team
Anbarasu Gowthamam
Dr. Gowtham has overseen several positions in clinical medicine and innovative research in integrative medicine in collaborations with major research institutes in United states, Australia and India. He ran cutting edge collaborative research projects with World Care Clinical, Harvard Medical School, Madras Medical College and Lupin Pharmaceuticals.
Judith Abeler
Judith Abeler is a Doctor of Human Medicine and a Specialist in internal medicine in Germany. Since 2013 she has worked clinically in cardiology, gastroenterology, internal medicine, and oncology.